Michael S Ritsner

Summary

Affiliation: Sha'ar Menashe Mental Health Center
Country: Israel

Publications

  1. ncbi Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: a naturalistic comparative study
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Hadera, Israel
    J Clin Psychopharmacol 24:245-54. 2004
  2. ncbi Temperament types are associated with weak self-construct, elevated distress and emotion-oriented coping in schizophrenia: evidence for a complex vulnerability marker?
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
    Psychiatry Res 128:219-28. 2004
  3. ncbi Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Mobile Post Hefer, 38814 Hadera, Israel
    Neuropsychopharmacology 30:1913-22. 2005
  4. ncbi Condensed version of the Quality of Life Scale for schizophrenia for use in outcome studies
    Michael Ritsner
    Pathological Behavior and Psychobiology Research Laboratory, Sha ar Menashe Mental Health Center, Hadera, Israel
    Psychiatry Res 135:65-75. 2005
  5. ncbi The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care
    Michael S Ritsner
    Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
    Prog Neuropsychopharmacol Biol Psychiatry 31:1470-7. 2007
  6. ncbi Predicting quality of life impairment in chronic schizophrenia from cognitive variables
    Michael S Ritsner
    The Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Qual Life Res 16:929-37. 2007
  7. ncbi Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Hadera, Israel
    Qual Life Res 14:1693-703. 2005
  8. ncbi Predicting domain-specific insight of schizophrenia patients from symptomatology, multiple neurocognitive functions, and personality related traits
    Michael S Ritsner
    Sha ar Menashe Mental Health Center, Hadera, Israel
    Psychiatry Res 149:59-69. 2007
  9. ncbi The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers
    Michael S Ritsner
    Sha ar Menashe Mental Health Center, Hadera, Israel
    Prog Neuropsychopharmacol Biol Psychiatry 30:1442-52. 2006
  10. ncbi Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial
    Michael S Ritsner
    Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    J Clin Psychopharmacol 26:495-9. 2006

Detail Information

Publications50

  1. ncbi Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: a naturalistic comparative study
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Hadera, Israel
    J Clin Psychopharmacol 24:245-54. 2004
    ..Satisfaction with medication together with subjective tolerability needs to be considered in clinical trials...
  2. ncbi Temperament types are associated with weak self-construct, elevated distress and emotion-oriented coping in schizophrenia: evidence for a complex vulnerability marker?
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
    Psychiatry Res 128:219-28. 2004
    ....
  3. ncbi Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Mobile Post Hefer, 38814 Hadera, Israel
    Neuropsychopharmacology 30:1913-22. 2005
    ..Thus, these data provide evidence that elevated serum cortisol and cortisol/DHEA(S) ratios may serve as markers of biological mechanisms that are involved in responsivity of schizophrenia patients to antipsychotic treatment...
  4. ncbi Condensed version of the Quality of Life Scale for schizophrenia for use in outcome studies
    Michael Ritsner
    Pathological Behavior and Psychobiology Research Laboratory, Sha ar Menashe Mental Health Center, Hadera, Israel
    Psychiatry Res 135:65-75. 2005
    ..Utilization of the revised QLS(5) in routine care and clinical trials may potentially facilitate evaluation of treatment outcomes in schizophrenia...
  5. ncbi The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care
    Michael S Ritsner
    Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
    Prog Neuropsychopharmacol Biol Psychiatry 31:1470-7. 2007
    ..This long-term observational study examined ziprasidone-induced improvement in satisfaction with HRQL in schizophrenia patients treated under real-world conditions...
  6. ncbi Predicting quality of life impairment in chronic schizophrenia from cognitive variables
    Michael S Ritsner
    The Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Qual Life Res 16:929-37. 2007
    ..The aim of this study was to see whether and how cognition deficit predicts quality of life impairments in schizophrenia patients...
  7. ncbi Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Hadera, Israel
    Qual Life Res 14:1693-703. 2005
    ..Thus, Q-LES-Q-18, a brief, self-administered questionnaire may aid in monitoring quality of life outcomes of schizophrenia, schizoaffective, and mood disorder patients...
  8. ncbi Predicting domain-specific insight of schizophrenia patients from symptomatology, multiple neurocognitive functions, and personality related traits
    Michael S Ritsner
    Sha ar Menashe Mental Health Center, Hadera, Israel
    Psychiatry Res 149:59-69. 2007
    ..The findings enable better understanding of the multifactorial nature of insight and highlight targets for more effective intervention and rehabilitation...
  9. ncbi The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers
    Michael S Ritsner
    Sha ar Menashe Mental Health Center, Hadera, Israel
    Prog Neuropsychopharmacol Biol Psychiatry 30:1442-52. 2006
    ....
  10. ncbi Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial
    Michael S Ritsner
    Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    J Clin Psychopharmacol 26:495-9. 2006
    ..In this study, the intention was to investigate the efficacy and safety of DHEA administration to ongoing antipsychotic medication in a multicenter, 12-week, double-blind, randomized, placebo-controlled, crossover trial...
  11. ncbi Coping patterns as a valid presentation of the diversity of coping responses in schizophrenia patients
    Michael S Ritsner
    Sha ar Menashe Mental Health Center, Hadera, Israel
    Psychiatry Res 144:139-52. 2006
    ..Coping patterns may be considered an important source of knowledge for patients who struggle with the illness and for mental health professionals who work with schizophrenia patients...
  12. ncbi State and trait related predictors of serum cortisol to DHEA(S) molar ratios and hormone concentrations in schizophrenia patients
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel The Rappaport Faculty of Medicine, Technion, Haifa, Israel
    Eur Neuropsychopharmacol 17:257-64. 2007
    ..The present study aimed to examine the contribution of anxiety, and severity of symptoms to the prediction of serum cortisol, DHEA(S) levels and two molar ratios across three examinations...
  13. ncbi Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Hadera, Israel
    J Clin Psychopharmacol 24:582-91. 2004
    ....
  14. ncbi Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
    Eur Neuropsychopharmacol 17:358-65. 2007
    ..The neurosteroid levels were monitored for two months and the relationship of these neurosteroids with schizophrenic symptomatology, emotional distress, and anxiety was examined...
  15. ncbi Determinants of changes in perceived quality of life in the course of schizophrenia
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Mobile Post Hefer, 38814, Hadera, Israel
    Qual Life Res 15:515-26. 2006
    ....
  16. ncbi Positive family history is associated with persistent elevated emotional distress in schizophrenia: evidence from a 16-month follow-up study
    Michael S Ritsner
    Sha ar Menashe Mental Health Center, Hadera, Israel Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
    Psychiatry Res 153:217-23. 2007
    ....
  17. doi Factor structure in the Camberwell Assessment of Need-Patient Version: the correlations with dimensions of illness, personality and quality of life of schizophrenia patients
    Michael S Ritsner
    Department of Psychiatry, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, and Sha ar Menashe Mental Health Center, Hadera, Israel
    Psychiatry Clin Neurosci 66:499-507. 2012
    ..To investigate the factor structure underlying the Camberwell Assessment of Need-Patient Version (CANSAS-P) items in schizophrenia and schizoaffective disorder...
  18. doi Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA
    Michael S Ritsner
    The Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Sha ar Menashe Mental Health Center, Hadera, Israel
    J Psychiatr Res 44:75-80. 2010
    ....
  19. doi Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorder II. Predictive value of psychosocial factors
    Michael S Ritsner
    Department of Psychiatry, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Qual Life Res 21:1075-84. 2012
    ..To identify psychosocial predictors of change in health-related quality of life among patients with schizophrenia (SZ) and schizoaffective (SA) disorders over a 10-year period...
  20. doi Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorders: I. Predictive value of disorder-related factors
    Michael S Ritsner
    Department of Psychiatry, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Qual Life Res 21:837-47. 2012
    ..To provide data on long-term health-related quality of life (HRQL) outcomes among patients with schizophrenia (SZ) and schizoaffective (SA) disorders and determine the predictive value of disorder-related factors...
  21. ncbi The long-term changes in coping strategies in schizophrenia: temporal coping types
    Michael S Ritsner
    Sha ar Menashe Mental Health Center, Hadera, Israel
    J Nerv Ment Dis 194:261-7. 2006
    ..The findings underscore the clinical relevance of temporal coping types and corroborate the appropriateness of focusing on aspects of coping behavior in treatment and rehabilitation of schizophrenia patients...
  22. doi Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial
    Anatoly Gibel
    Sha ar Menashe Mental Health Center, Hadera, Israel
    Clin Neuropharmacol 31:204-20. 2008
    ..Two questions were addressed in the present report: whether cognitive improvement would occur during 12-month ziprasidone treatment and whether the changes in cognitive functioning are dependent of changes in the illness-related variables...
  23. doi Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial
    Michael S Ritsner
    Department of Psychiatry, The Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    J Clin Psychiatry 71:1351-62. 2010
    ..We investigated the influence of PREG and DHEA on psychotic symptoms and cognitive functioning as an add-on to ongoing antipsychotic treatment of patients with chronic schizophrenia or schizoaffective disorder...
  24. doi L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study
    Michael S Ritsner
    Department of Psychiatry, The Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel
    J Clin Psychiatry 72:34-42. 2011
    ..This is a first study designed to evaluate the efficacy and tolerability of L-theanine augmentation of antipsychotic treatment of patients with chronic schizophrenia and schizoaffective disorder...
  25. ncbi Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial
    Yael Ratner
    Acute Department, Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Hadera, Israel
    Prog Neuropsychopharmacol Biol Psychiatry 31:1401-9. 2007
    ....
  26. doi Symptom severity scale of the DSM5 for schizophrenia, and other psychotic disorders: diagnostic validity and clinical feasibility
    Michael S Ritsner
    Department of Psychiatry, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa and Sha ar Menashe Mental Health Center, Israel
    Psychiatry Res 208:1-8. 2013
    ..The dimensional option for the diagnosis of schizophrenia and related disorders using SS-DSM5 is discussed...
  27. ncbi Predictors of quality of life in major psychoses: a naturalistic follow-up study
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Hadera, Israel
    J Clin Psychiatry 64:308-15. 2003
    ..We sought to determine predictors of perceived QOL and to explore the changes that occur regarding QOL among individuals with schizophrenia as compared to patients with schizoaffective/mood disorders...
  28. ncbi Perceived quality of life in schizophrenia: relationships to sleep quality
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Hadera, Israel
    Qual Life Res 13:783-91. 2004
    ..Thus, poor QOL reported by schizophrenia patients is substantially associated with poor sleep quality. This association appears both independently and synergistically with depression, distress and side effects of medications...
  29. ncbi Alterations in DHEA metabolism in schizophrenia: two-month case-control study
    Michael Ritsner
    Acute Department and Clinical Psychobiology Laboratory, Sha ar Menashe Mental Health Center, Mobile Post Hefer, Hadera, Israel
    Eur Neuropsychopharmacol 16:137-46. 2006
    ....
  30. doi Anhedonia is an important factor of health-related quality-of-life deficit in schizophrenia and schizoaffective disorder
    Michael S Ritsner
    Department of Psychiatry, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    J Nerv Ment Dis 199:845-53. 2011
    ..Therefore, physical and social hedonic deficits significantly associated with poor HRQL independent of the adverse effects and psychopathological symptoms of SZ/SA. Physical anhedonia may be a predictor for quality-of-life deficit...
  31. ncbi Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Mobile Post Hefer, Hadera, Israel
    Eur Neuropsychopharmacol 14:267-73. 2004
    ....
  32. ncbi The detection of neurocognitive decline in schizophrenia using the Mindstreams Computerized Cognitive Test Battery
    Michael S Ritsner
    Cognitive and Psychobiology Research Laboratory, Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
    Schizophr Res 82:39-49. 2006
    ..The aim of the present study was to determine the ability of Mindstreams in detecting cognitive dysfunction in schizophrenia patients and to compare it to the Cambridge Neuropsychological Test Automated Battery (CANTAB)...
  33. ncbi Predicting changes in domain-specific quality of life of schizophrenia patients
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Hadera, Israel
    J Nerv Ment Dis 191:287-94. 2003
    ..Changes in stress process-related factors are stronger predictors of fluctuations in QOL domains than changes in illness symptoms and should be considered when evaluating life satisfaction...
  34. ncbi Satisfaction with quality of life varies with temperament types of patients with schizophrenia
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
    J Nerv Ment Dis 191:668-74. 2003
    ..Novelty seeking, reward dependence, and harm avoidance are associated with different domains of QOL...
  35. doi Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials
    Michael S Ritsner
    Psychiatry Department, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, and Sha ar Menashe Mental Health Center, Israel
    CNS Neurosci Ther 16:32-44. 2010
    ..This review also provides substantial information about clinical trials with DHEA and PREG augmentation with of antipsychotic agents in schizophrenia...
  36. ncbi Life satisfaction and suicidal attempts among persons with schizophrenia
    Alexander M Ponizovsky
    Sha ar Menashe Mental Health Center, Hadera, Israel
    Compr Psychiatry 44:442-7. 2003
    ..Clinicians should include QOL in the evaluation of patients with schizophrenia that are suspected to be suicidal...
  37. ncbi The attribution of somatization in schizophrenia patients: a naturalistic follow-up study
    Michael Ritsner
    Sha ar Menashe Mental Health Center, and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
    J Clin Psychiatry 64:1370-8. 2003
    ..This study aimed to explore the prevalence, correlates, and predictors of somatization among schizophrenia patients...
  38. ncbi Age differences in stress process of recent immigrants
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Hadera, Israel
    Compr Psychiatry 44:135-41. 2003
    ..Thus, age differences in the stress process of recent immigrants are associated with age-specific perceived adjustment difficulties and demographic characteristics...
  39. ncbi The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study
    Michael Ritsner
    Institute for Psychiatric Studies, Sha ar Menashe Mental Health Center, Hadera, Israel
    Eur Neuropsychopharmacol 12:31-8. 2002
    ..Patient's subjective response to these events rather than their number is more predictive of QOL...
  40. ncbi Decreased platelet peripheral-type benzodiazepine receptors in persistently violent schizophrenia patients
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
    J Psychiatr Res 37:549-56. 2003
    ....
  41. ncbi Quality of life and temperament factors in schizophrenia: comparative study of patients, their siblings and controls
    Rena Kurs
    Sha ar Meashe Mental Health Centre, Mobile Post Hefer 38814, Israel
    Qual Life Res 14:433-40. 2005
    ..These and other non-illness related factors should be considered when evaluating quality of life outcomes in intervention studies...
  42. ncbi Predicting 10-year quality-of-life outcomes of patients with schizophrenia and schizoaffective disorders
    Michael S Ritsner
    Sha ar Menashe Mental Health Center, Israel affiliated to the Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Psychiatry Clin Neurosci 68:308-17. 2014
    ..This study aimed to determine predictors for 10-year good versus poor perceived general quality of life (QOL) outcomes from baseline variables in people with schizophrenia and schizoaffective disorder...
  43. ncbi Familiality in a five-factor model of schizophrenia psychopathology: findings from a 16-month follow-up study
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Hadera, Israel
    Psychiatry Res 136:173-9. 2005
    ..It is suggested that dysphoric mood may be a useful phenotype for molecular genetic studies of schizophrenia with positive family history...
  44. ncbi Association study of CAG repeats in the KCNN3 gene in Israeli patients with major psychosis
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Hadera, Israel
    Psychiatr Genet 13:143-50. 2003
    ..We investigated the contribution of the CAG repeat at the KCNN3 gene, localized to chromosome 1q21.3, to the genetic susceptibility for schizophrenia, schizoaffective and bipolar disorders...
  45. ncbi Neural network identification of high-risk suicide patients
    Ilan Modai
    Sh ar Menashe Mental Health Center, Institute of Psychiatric Studies, Hadera, Israel
    Med Inform Internet Med 27:39-47. 2002
    ..Backpropagation (BP) neural networks (NN) successfully detected patient files of patients who had committed MSSA but failed to identify MSSA patients when trained with data collected during face-to-face interviews...
  46. ncbi An association of CAG repeats at the KCNN3 locus with symptom dimensions of schizophrenia
    Michael Ritsner
    Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Hadera, Israel
    Biol Psychiatry 51:788-94. 2002
    ..There has been no attempt to replicate the results. In this study, we investigated whether a symptom polymorphism of schizophrenia is associated with both the CAG repeat numbers and the difference in allele sizes...
  47. ncbi Assessing psychological distress in psychiatric patients: validation of the Talbieh Brief Distress Inventory
    Michael Ritsner
    Institute for Psychiatric Studies, Sha ar Menashe Mental Health Center, Hadera, Israel
    Compr Psychiatry 43:229-34. 2002
    ....
  48. ncbi Patterns of loneliness in an immigrant population
    Alexander M Ponizovsky
    Mental Health Services, Department of Research and Planning, Ministry of Health, Jerusalem, Israel
    Compr Psychiatry 45:408-14. 2004
    ..An important implication of this study in mental health practice is the sensitivity to these differences when treating recent immigrants...
  49. doi Hormonal response to dehydroepiandrosterone administration in schizophrenia: findings from a randomized, double-blind, placebo-controlled, crossover study
    Rael David Strous
    J Clin Psychopharmacol 28:456-9. 2008
  50. doi Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial
    Vladimir Lerner
    Division of Psychiatry, Ministry of Health Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Be er Sheva, Israel
    Clin Neuropharmacol 31:25-33. 2008
    ..This study is the first to investigate the safety and efficacy of add-on oral bexarotene to ongoing antipsychotic treatment in chronic schizophrenia patients who were stabilized on regular antipsychotic treatment...